VALENCIA, Calif. — MannKind Corp. said Monday the Food and Drug Administration will allow the drug developer to begin human testing of one of its cancer treatments.
The company said it can now begin early-stage clinical trials on its experimental cancer drug, MKC1106-PP.
Enrollment of the trial's first patient is expected by the end of the year. The study will test the safety and tolerability of the drug in patients with solid tumors.
source - AP
